Abdel Rahman Hala Aly, Khorshied Mervat Mamdooh, Reda Khorshid Ola Mohamed, Mourad Heba Mahmoud
Cairo University Kasr Alainy Faculty of Medicine, Department of Clinical and Chemical Pathology, Cairo, Egypt.
Cairo University National Cancer Institute, Department of Medical Oncology, Cairo, Egypt.
Turk J Haematol. 2018 May 25;35(2):99-108. doi: 10.4274/tjh.2017.0106. Epub 2017 Jul 17.
Polymorphisms in the interleukin (IL)-2 and IL-10 genes are known to be associated with susceptibility to different immune-dysregulated disorders and cancers such as non-Hodgkin lymphoma (NHL). To explore the possible association between IL-2-330T/G and IL-10-1082A/G single-nucleotide polymorphisms and the susceptibility to B-cell NHL (B-NHL) in Egyptians, we conducted a case-control study.
Genotyping of the studied genetic variations was done for 100 B-NHL patients as well as 100 age- and sex-matched healthy controls.
The IL-2 variant allele occurred at a significantly higher rate in patients than controls and was associated with susceptibility to B-NHL [odds ratio (OR): 1.91, 95% confidence interval (CI): 1.28-2.85]. It was also associated with advanced performance status score. IL-2 polymorphism conferred an almost threefold increased risk of diffuse large B-cell lymphoma (OR: 2.64, 95% CI: 1.35-5.15) and a fourfold increased risk of indolent subtypes (OR: 4.34, 95% CI: 1.20-15.7). The distribution of IL-10-1082A/G genotypes in our patients was close to that of the controls. Co-inheritance of the variant genotypes of IL-2 and the common genotype of IL-10 conferred an almost sixfold increased risk (OR: 5.75, 95% CI: 1.39-23.72), while co-inheritance of the variant genotypes of IL-2 and IL-10 conferred fivefold increased risk of B-NHL (OR: 5.43, 95% CI: 1.44-20.45). The variant genotypes of IL-2-330T/G and IL-10-1082A/G had no effect on the disease-free survival of B-NHL patients.
The present study highlights the possible involvement of the IL-2-330T/G genetic polymorphism in the susceptibility to B-NHL in Egypt, especially indolent subtypes. Moreover, IL-10-1082A/G is not a molecular susceptibility marker for B-NHL in Egyptians.
已知白细胞介素(IL)-2和IL-10基因多态性与不同免疫失调疾病和癌症(如非霍奇金淋巴瘤(NHL))的易感性相关。为了探讨IL-2 - 330T/G和IL-10 - 1082A/G单核苷酸多态性与埃及人B细胞NHL(B-NHL)易感性之间的可能关联,我们进行了一项病例对照研究。
对100例B-NHL患者以及100例年龄和性别匹配的健康对照进行了所研究基因变异的基因分型。
IL-2变异等位基因在患者中的出现率显著高于对照组,并且与B-NHL易感性相关[比值比(OR):1.91,95%置信区间(CI):1.28 - 2.85]。它还与较高的体能状态评分相关。IL-2基因多态性使弥漫性大B细胞淋巴瘤风险增加近三倍(OR:2.64,95% CI:1.35 - 5.15),惰性亚型风险增加四倍(OR:4.34,95% CI:1.20 - 15.7)。我们患者中IL-10 - 1082A/G基因型的分布与对照组接近。IL-2变异基因型与IL-10常见基因型的共同遗传使风险增加近六倍(OR:5.75,95% CI:1.39 - 23.72),而IL-2和IL-10变异基因型的共同遗传使B-NHL风险增加五倍(OR:5.43,95% CI:1.44 - 20.45)。IL-2 - 330T/G和IL-10 - 1082A/G变异基因型对B-NHL患者的无病生存期没有影响。
本研究强调了IL-2 - 330T/G基因多态性可能参与埃及人对B-NHL的易感性,尤其是惰性亚型。此外,IL-10 - 1082A/G不是埃及人B-NHL的分子易感性标志物。